Health Care • Biotechnology: Pharmaceutical Preparations
$3.66 ▲ +0.01
(+0.27%)
MKT CAP: $364.0M • VOL: 2.04M
52W L $3 52W H $13
SPRY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $84.3M | $89.1M | $30.0K |
| YoY Revenue Growth % | -5.5% | +297063.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$179.4M | -$3.1M | -$67.5M |
| Operating Margin % | -80.0% | -3.5% | -80.0% |
| Net Income (GAAP) | -$171.3M | $8.0M | -$54.4M |
| EBITDA (Normalized) | -$179.2M | -$2.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$170.9M | $13.5M | -$59.3M |
| Capital Expenditures (CapEx) | $339.0K | $563.0K | — |
| Free Cash Flow (FCF) | -$171.2M | $13.0M | -$59.3M |
| FCF Margin % | -80.0% | 14.6% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -1.2% | — |
| Cash & Short-Term Equivalents | $41.3M | $50.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $114.3M | $256.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SPRY.